Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.Neovascularization, Physiologic: The development of new BLOOD VESSELS during the restoration of BLOOD CIRCULATION during the healing process.Angiogenesis Inducing Agents: Agents that induce or stimulate PHYSIOLOGIC ANGIOGENESIS or PATHOLOGIC ANGIOGENESIS.Vascular Endothelial Growth Factor A: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.Endothelial Cells: Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer.Vascular Endothelial Growth Factors: A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.Endothelial Growth Factors: These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesize DNA. The factors are related to both the basic and acidic FIBROBLAST GROWTH FACTORS but have different amino acid sequences.Endothelium, Vascular: Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.Vascular Endothelial Growth Factor Receptor-2: A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.Lymphokines: Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity.Angiogenic Proteins: Intercellular signaling peptides and proteins that regulate the proliferation of new blood vessels under normal physiological conditions (ANGIOGENESIS, PHYSIOLOGICAL). Aberrant expression of angiogenic proteins during disease states such as tumorigenesis can also result in PATHOLOGICAL ANGIOGENESIS.Angiogenesis Modulating Agents: Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents.Human Umbilical Vein Endothelial Cells: Endothelial cells that line venous vessels of the UMBILICAL CORD.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Chorioallantoic Membrane: A highly vascularized extra-embryonic membrane, formed by the fusion of the CHORION and the ALLANTOIS. It is mostly found in BIRDS and REPTILES. It serves as a model for studying tumor or cell biology, such as angiogenesis and TISSUE TRANSPLANTATION.Capillaries: The minute vessels that connect the arterioles and venules.Fibroblast Growth Factor 2: A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Blood Vessels: Any of the tubular vessels conveying the blood (arteries, arterioles, capillaries, venules, and veins).Allantois: An extra-embryonic membranous sac derived from the YOLK SAC of REPTILES; BIRDS; and MAMMALS. It lies between two other extra-embryonic membranes, the AMNION and the CHORION. The allantois serves to store urinary wastes and mediate exchange of gas and nutrients for the developing embryo.Antigens, CD31: Cell adhesion molecules present on virtually all monocytes, platelets, and granulocytes. CD31 is highly expressed on endothelial cells and concentrated at the junctions between them.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Receptors, Vascular Endothelial Growth Factor: A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.Corneal Neovascularization: New blood vessels originating from the corneal veins and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.Angiopoietin-2: An angiopoietin that is closely related to ANGIOPOIETIN-1. It binds to the TIE-2 RECEPTOR without receptor stimulation and antagonizes the effect of ANGIOPOIETIN-1. However its antagonistic effect may be limited to cell receptors that occur within the vasculature. Angiopoietin-2 may therefore play a role in down-regulation of BLOOD VESSEL branching and sprouting.Angiopoietin-1: The first to be discovered member of the angiopoietin family. It may play a role in increasing the sprouting and branching of BLOOD VESSELS. Angiopoietin-1 specifically binds to and stimulates the TIE-2 RECEPTOR. Several isoforms of angiopoietin-1 occur due to ALTERNATIVE SPLICING of its mRNA.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.Thrombospondin 1: An extracellular matrix glycoprotein from platelets and a variety of normal and transformed cells of both mesenchymal and epithelial origin. Thrombospondin-1 is believed to play a role in cell migration and proliferation, during embryogenesis and wound repair. Also, it has been studied for its use as a potential regulator of tumor growth and metastasis.Umbilical Veins: Venous vessels in the umbilical cord. They carry oxygenated, nutrient-rich blood from the mother to the FETUS via the PLACENTA. In humans, there is normally one umbilical vein.Receptor, TIE-2: A TIE receptor tyrosine kinase that is found almost exclusively on ENDOTHELIAL CELLS. It is required for both normal embryonic vascular development (NEOVASCULARIZATION, PHYSIOLOGIC) and tumor angiogenesis (NEOVASCULARIZATION, PATHOLOGIC).Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Cell Line, Tumor: A cell line derived from cultured tumor cells.Chorion: The outermost extra-embryonic membrane surrounding the developing embryo. In REPTILES and BIRDS, it adheres to the shell and allows exchange of gases between the egg and its environment. In MAMMALS, the chorion evolves into the fetal contribution of the PLACENTA.Hindlimb: Either of two extremities of four-footed non-primate land animals. It usually consists of a FEMUR; TIBIA; and FIBULA; tarsals; METATARSALS; and TOES. (From Storer et al., General Zoology, 6th ed, p73)Microvessels: The finer blood vessels of the vasculature that are generally less than 100 microns in internal diameter.Mice, Inbred C57BLHypoxia-Inducible Factor 1, alpha Subunit: Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Vascular Endothelial Growth Factor Receptor-1: A 180-kDa VEGF receptor found primarily in endothelial cells that is essential for vasculogenesis and vascular maintenance. It is also known as Flt-1 (fms-like tyrosine kinase receptor-1). A soluble, alternatively spliced isoform of the receptor may serve as a binding protein that regulates the availability of various ligands for VEGF receptor binding and signal transduction.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Endostatins: Angiostatic proteins that are formed from proteolytic cleavage of COLLAGEN TYPE XVIII.Microcirculation: The circulation of the BLOOD through the MICROVASCULAR NETWORK.Integrin alphaVbeta3: An integrin that binds to a variety of plasma and extracellular matrix proteins containing the conserved RGD amino acid sequence and modulates cell adhesion. Integrin alphavbeta3 is highly expressed in OSTEOCLASTS where it may play role in BONE RESORPTION. It is also abundant in vascular smooth muscle and endothelial cells, and in some tumor cells, where it is involved in angiogenesis and cell migration. Although often referred to as the vitronectin receptor there is more than one receptor for vitronectin (RECEPTORS, VITRONECTIN).Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Retinal Neovascularization: Formation of new blood vessels originating from the retinal veins and extending along the inner (vitreal) surface of the retina.Intercellular Signaling Peptides and Proteins: Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal.Laminin: Large, noncollagenous glycoprotein with antigenic properties. It is localized in the basement membrane lamina lucida and functions to bind epithelial cells to the basement membrane. Evidence suggests that the protein plays a role in tumor invasion.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.Drug Combinations: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Wound Healing: Restoration of integrity to traumatized tissue.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Chick Embryo: The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching.Cyclohexanes: Six-carbon alicyclic hydrocarbons.Angiostatins: Circulating 38-kDa proteins that are internal peptide fragments of PLASMINOGEN. The name derives from the fact that they are potent ANGIOGENESIS INHIBITORS. Angiostatins contain four KRINGLE DOMAINS which are associated with their potent angiostatic activity.Pericytes: Unique slender cells with multiple processes extending along the capillary vessel axis and encircling the vascular wall, also called mural cells. Pericytes are imbedded in the BASEMENT MEMBRANE shared with the ENDOTHELIAL CELLS of the vessel. Pericytes are important in maintaining vessel integrity, angiogenesis, and vascular remodeling.Collagen: A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH).Transplantation, Heterologous: Transplantation between animals of different species.Proteoglycans: Glycoproteins which have a very high polysaccharide content.Receptors, Growth Factor: Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Cell Hypoxia: A condition of decreased oxygen content at the cellular level.Retinal Vessels: The blood vessels which supply and drain the RETINA.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Mice, Inbred BALB CLymphangiogenesis: The formation of LYMPHATIC VESSELS.Angiopoietins: A family of structurally-related angiogenic proteins of approximately 70 kDa in size. They have high specificity for members of the TIE RECEPTOR FAMILY.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Up-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Receptor Protein-Tyrosine Kinases: A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.Mice, SCID: Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.Angiostatic Proteins: Proteins that specifically inhibit the growth of new blood vessels (ANGIOGENESIS, PHYSIOLOGIC).Cornea: The transparent anterior portion of the fibrous coat of the eye consisting of five layers: stratified squamous CORNEAL EPITHELIUM; BOWMAN MEMBRANE; CORNEAL STROMA; DESCEMET MEMBRANE; and mesenchymal CORNEAL ENDOTHELIUM. It serves as the first refracting medium of the eye. It is structurally continuous with the SCLERA, avascular, receiving its nourishment by permeation through spaces between the lamellae, and is innervated by the ophthalmic division of the TRIGEMINAL NERVE via the ciliary nerves and those of the surrounding conjunctiva which together form plexuses. (Cline et al., Dictionary of Visual Science, 4th ed)Matrix Metalloproteinase 2: A secreted endopeptidase homologous with INTERSTITIAL COLLAGENASE, but which possesses an additional fibronectin-like domain.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Matrix Metalloproteinase 9: An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V.Culture Media, Conditioned: Culture media containing biologically active components obtained from previously cultured cells or tissues that have released into the media substances affecting certain cell functions (e.g., growth, lysis).Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Proto-Oncogene Proteins c-akt: A protein-serine-threonine kinase that is activated by PHOSPHORYLATION in response to GROWTH FACTORS or INSULIN. It plays a major role in cell metabolism, growth, and survival as a core component of SIGNAL TRANSDUCTION. Three isoforms have been described in mammalian cells.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Thrombospondins: A family of related, adhesive glycoproteins which are synthesized, secreted, and incorporated into the extracellular matrix of a variety of cells, including alpha granules of platelets following thrombin activation and endothelial cells. They interact with a number of BLOOD COAGULATION FACTORS and anticoagulant factors. Five distinct forms have been identified, thrombospondin 1, -2, -3, -4, and cartilage oligomeric matrix protein (COMP). They are involved in cell adhesion, platelet aggregation, cell proliferation, angiogenesis, tumor metastasis, VASCULAR SMOOTH MUSCLE growth, and tissue repair.Anoxia: Relatively complete absence of oxygen in one or more tissues.Hypoxia-Inducible Factor 1: A basic helix-loop-helix transcription factor that plays a role in APOPTOSIS. It is composed of two subunits: ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR and HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT.Collagen Type XVIII: A non-fibrillar collagen found in BASEMENT MEMBRANE. The C-terminal end of the alpha1 chain of collagen type XVIII contains the ENDOSTATIN peptide, which can be released by proteolytic cleavage.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Capillary Permeability: The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement.Genetic Therapy: Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.SesquiterpenesPhosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.Mice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Cell Adhesion: Adherence of cells to surfaces or to other cells.Melanoma, Experimental: Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.Gene Expression Regulation: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.Thymidine Phosphorylase: An enzyme that catalyzes the transfer of 2-deoxy-D-ribose from THYMIDINE to orthophosphate, thereby liberating thymidine.Matrix Metalloproteinase Inhibitors: Compounds that inhibit the enzyme activity or activation of MATRIX METALLOPROTEINASES.Neuropilin-1: Dimeric cell surface receptor involved in angiogenesis (NEOVASCULARIZATION, PHYSIOLOGICAL) and axonal guidance. Neuropilin-1 is a 140-kDa transmembrane protein that binds CLASS 3 SEMAPHORINS, and several other growth factors. Neuropilin-1 forms complexes with plexins or VEGF RECEPTORS, and binding affinity and specificity are determined by the composition of the neuropilin dimer and the identity of other receptors complexed with it. Neuropilin-1 is expressed in distinct patterns during neural development, complementary to those described for NEUROPILIN-2.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Cell Growth Processes: Processes required for CELL ENLARGEMENT and CELL PROLIFERATION.Models, Biological: Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.Granulation Tissue: A vascular connective tissue formed on the surface of a healing wound, ulcer, or inflamed tissue. It consists of new capillaries and an infiltrate containing lymphoid cells, macrophages, and plasma cells.Skin: The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Paracrine Communication: Cellular signaling in which a factor secreted by a cell affects other cells in the local environment. This term is often used to denote the action of INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS on surrounding cells.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Stem Cells: Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.Matrix Metalloproteinases: A family of zinc-dependent metalloendopeptidases that is involved in the degradation of EXTRACELLULAR MATRIX components.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Aorta: The main trunk of the systemic arteries.Chemotaxis: The movement of cells or organisms toward or away from a substance in response to its concentration gradient.Cattle: Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Zebrafish: An exotic species of the family CYPRINIDAE, originally from Asia, that has been introduced in North America. They are used in embryological studies and to study the effects of certain chemicals on development.Nitric Oxide Synthase Type III: A CALCIUM-dependent, constitutively-expressed form of nitric oxide synthase found primarily in ENDOTHELIAL CELLS.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)Lung Neoplasms: Tumors or cancer of the LUNG.Pregnancy Proteins: Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)Breast Neoplasms: Tumors or cancer of the human BREAST.Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Vascular Endothelial Growth Factor B: A vascular endothelial growth factor expressed in a variety of tissues. It binds with high specificity to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 and NEUROPILIN-1.Vascular Endothelial Growth Factor C: A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR D in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.Extracellular Matrix: A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.Endothelium: A layer of epithelium that lines the heart, blood vessels (ENDOTHELIUM, VASCULAR), lymph vessels (ENDOTHELIUM, LYMPHATIC), and the serous cavities of the body.Cyclooxygenase 2: An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS.Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.Surgical Sponges: Gauze material used to absorb body fluids during surgery. Referred to as GOSSYPIBOMA if accidentally retained in the body following surgery.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Receptors, Vitronectin: Receptors such as INTEGRIN ALPHAVBETA3 that bind VITRONECTIN with high affinity and play a role in cell migration. They also bind FIBRINOGEN; VON WILLEBRAND FACTOR; osteopontin; and THROMBOSPONDINS.Collateral Circulation: Maintenance of blood flow to an organ despite obstruction of a principal vessel. Blood flow is maintained through small vessels.Enzyme Inhibitors: Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.Ribonuclease, Pancreatic: An enzyme that catalyzes the endonucleolytic cleavage of pancreatic ribonucleic acids to 3'-phosphomono- and oligonucleotides ending in cytidylic or uridylic acids with 2',3'-cyclic phosphate intermediates. EC 3.1.27.5.Receptors, Cell Surface: Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.Hepatocyte Growth Factor: Multifunctional growth factor which regulates both cell growth and cell motility. It exerts a strong mitogenic effect on hepatocytes and primary epithelial cells. Its receptor is PROTO-ONCOGENE PROTEINS C-MET.Coculture Techniques: A technique of culturing mixed cell types in vitro to allow their synergistic or antagonistic interactions, such as on CELL DIFFERENTIATION or APOPTOSIS. Coculture can be of different types of cells, tissues, or organs from normal or disease states.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Extracellular Signal-Regulated MAP Kinases: A mitogen-activated protein kinase subfamily that is widely expressed and plays a role in regulation of MEIOSIS; MITOSIS; and post mitotic functions in differentiated cells. The extracellular signal regulated MAP kinases are regulated by a broad variety of CELL SURFACE RECEPTORS and can be activated by certain CARCINOGENS.Semaphorins: A family of proteins that mediate axonal guidance. Semaphorins act as repulsive cues for neuronal GROWTH CONES and bind to receptors on their filopodia. At least 20 different molecules have been described and divided into eight classes based on domain organization and species of origin. Classes 1 and 2 are invertebrate, classes 3-7 are vertebrate, and class V are viral. Semaphorins may be secreted (classes 2, 3, and V), transmembrane (classes 1, 4, 5, and 6), or membrane-anchored (class 7). All semaphorins possess a common 500-amino acid extracellular domain which is critical for receptor binding and specificity, and is also found in plexins and scatter factor receptors. Their C termini are class-specific and may contain additional sequence motifs.Adenoviridae: A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases.Ephrin-B2: A transmembrane domain containing ephrin that binds with high affinity to EPHB1 RECEPTOR; EPHB3 RECEPTOR; and EPHB4 RECEPTOR. Expression of ephrin-B2 occurs in a variety of adult tissues. During embryogenesis, high levels of ephrin-B2 is seen in the PROSENCEPHALON; RHOMBENCEPHALON; developing SOMITES; LIMB BUD; and bronchial arches.Growth Substances: Signal molecules that are involved in the control of cell growth and differentiation.Pyrroles: Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.RNA Interference: A gene silencing phenomenon whereby specific dsRNAs (RNA, DOUBLE-STRANDED) trigger the degradation of homologous mRNA (RNA, MESSENGER). The specific dsRNAs are processed into SMALL INTERFERING RNA (siRNA) which serves as a guide for cleavage of the homologous mRNA in the RNA-INDUCED SILENCING COMPLEX. DNA METHYLATION may also be triggered during this process.Peptide Fragments: Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Regional Blood Flow: The flow of BLOOD through or around an organ or region of the body.Stromal Cells: Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.PhthalazinesTumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Membrane Proteins: Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.Oligopeptides: Peptides composed of between two and twelve amino acids.Laser-Doppler Flowmetry: A method of non-invasive, continuous measurement of MICROCIRCULATION. The technique is based on the values of the DOPPLER EFFECT of low-power laser light scattered randomly by static structures and moving tissue particulates.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Integrin alphaV: An alpha integrin with a molecular weight of 160-kDa that is found in a variety of cell types. It undergoes posttranslational cleavage into a heavy and a light chain that are connected by disulfide bonds. Integrin alphaV can combine with several different beta subunits to form heterodimers that generally bind to RGD sequence-containing extracellular matrix proteins.Fibroblasts: Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.Gene Knockdown Techniques: The artificial induction of GENE SILENCING by the use of RNA INTERFERENCE to reduce the expression of a specific gene. It includes the use of DOUBLE-STRANDED RNA, such as SMALL INTERFERING RNA and RNA containing HAIRPIN LOOP SEQUENCE, and ANTI-SENSE OLIGONUCLEOTIDES.Vascular Endothelial Growth Factor Receptor-3: A vascular endothelial cell growth factor receptor whose expression is restricted primarily to adult lymphatic endothelium. VEGFR-3 preferentially binds the vascular endothelial growth factor C and vascular endothelial growth factor D and may be involved in the control of lymphangiogenesis.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Phosphatidylinositol 3-Kinases: Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell.Muscle, Skeletal: A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.Indoles: Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Gene Transfer Techniques: The introduction of functional (usually cloned) GENES into cells. A variety of techniques and naturally occurring processes are used for the gene transfer such as cell hybridization, LIPOSOMES or microcell-mediated gene transfer, ELECTROPORATION, chromosome-mediated gene transfer, TRANSFECTION, and GENETIC TRANSDUCTION. Gene transfer may result in genetically transformed cells and individual organisms.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Plasminogen: Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent.Models, Animal: Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.Receptors, Notch: A family of conserved cell surface receptors that contain EPIDERMAL GROWTH FACTOR repeats in their extracellular domain and ANKYRIN repeats in their cytoplasmic domains. The cytoplasmic domain of notch receptors is released upon ligand binding and translocates to the CELL NUCLEUS where it acts as transcription factor.Neuropilins: Neuropilins are 140-kDa vertebrate cell surface receptors that bind neuronal guidance molecules during neural development and axonal outgrowth, and modulate VEGF-mediated angiogenesis. NEUROPILIN-1 and NEUROPILIN-2 differ in their binding specificities, and are distributed complementarily in regions of the developing nervous system. Neuropilins are receptors for secreted CLASS 3 SEMAPHORINS as well as for vascular endothelial growth factors, and may form hetero- or homodimers. They may also interact synergistically with plexins and with VEGF RECEPTORS to form receptor complexes with distinct affinities and specificities. Neuropilin binding specificity is determined by CUB and coagulation-factor-like domains in the extracellular portion of the molecule, while a MAM domain is essential for SIGNAL TRANSDUCTION.Rats, Wistar: A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.Colonic Neoplasms: Tumors or cancer of the COLON.Receptor, EphB4: An eph family receptor found in a variety of adult and embryonic tissues. Unlike the majority of proteins in this class there is little or no expression of EphB4 receptor in the BRAIN. It has been found at high levels in developing mammary glands and in invasive mammary tumors.Chemokine CXCL12: A CXC chemokine that is chemotactic for T-LYMPHOCYTES and MONOCYTES. It has specificity for CXCR4 RECEPTORS. Two isoforms of CXCL12 are produced by alternative mRNA splicing.Tumor Microenvironment: The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.Enzyme Activation: Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.Mammary Neoplasms, Experimental: Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.In Situ Hybridization: A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.Receptors, TIE: A family of structurally-related tyrosine kinase receptors that are expressed predominantly in ENDOTHELIAL CELLS and are essential for development of BLOOD VESSELS (NEOVASCULARIZATION, PHYSIOLOGIC). The name derives from the fact that they are tyrosine kinases that contain Ig and EGF domains.Rats, Nude: A mutant strain of Rattus norvegicus without a thymus and with depressed or absent T-cell function. This strain of rats may have a small amount of hair at times, but then lose it.Macrophages: The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)Serpins: A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition, but differ in their specificity toward proteolytic enzymes. This family includes alpha 1-antitrypsin, angiotensinogen, ovalbumin, antiplasmin, alpha 1-antichymotrypsin, thyroxine-binding protein, complement 1 inactivators, antithrombin III, heparin cofactor II, plasminogen inactivators, gene Y protein, placental plasminogen activator inhibitor, and barley Z protein. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES, and some serpins occur in plants where their function is not known.Genetic Vectors: DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.Nitric Oxide: A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP.

Endometriotic disease: the role of peritoneal fluid. (1/782)

Peritoneal fluid and the intraovarian milieu are a specific microenvironment. Peritoneal fluid originates mainly as an ovarian exudation product caused by increased vascular permeability, with cyclic variation in volume and steroid hormones which are always higher than in plasma. It contains large amounts of macrophages and their secretion products, and has a large exchange area with plasma through the peritoneum, which is highly permeable for small molecules. Diffusion becomes virtually zero for molecules with a molecular weight of >100000 Da. In women with the luteinized unruptured follicle (LUF) syndrome, concentrations of oestrogens and progesterone are much lower in the luteal phase. Endometriosis is associated with sterile low-grade inflammation, increased concentrations of activated macrophages and many of their secretions, such as cytokines, growth factors and angiogenic factors. Concentrations of CA-125 and of glycodelins are also increased, secreted locally by the endometrial cells. Natural killer (NK) cell function declines, possibly mediated by glycodelins or local intercellular adhesion molecule (ICAM) -1 shedding. The ovary is also a specific microenvironment, with steroid hormone concentrations 1000-fold higher in follicles than in plasma. Endometrial and superficially implanted cells are influenced by peritoneal fluid concentrations so that local environment, rather than inherent cellular differences could explain differences between superficial endometriosis and eutopic endometrium. Differences between superficial implants and endometriotic disease, deep infiltrating or cystic ovarian endometriosis, may thus arise via different endocrine environments. Superficial endometrial implants are regulated by peritoneal fluid factors, whereas deep endometriosis and cystic ovarian endometriosis are influenced by blood or ovarian factors. The endometriotic disease theory considers superficial endometriotic implants and their remodelling as a physiological process in most women, and concentrates on the causes of severe endometriosis such as differences in the eutopic endometrium from women with and without endometriosis (which may indicate hereditary differences), the invasiveness of some endometriotic cells in vitro, focal 'shielding' of endometriotic foci by adhesions, and inhibition of NK activity by ICAM-1 and glycodelins. Endometriotic disease is thus seen as a benign tumour. The type of cellular lesion, hereditary and immunological environments and local hormone concentrations in the ovary and in peritoneal fluid, will decide expression as cystic ovarian endometriosis, deep endometriosis or adenomyosis externa, and whether the latter is associated with adhesions.  (+info)

Stimulation of tumour growth by wound-derived growth factors. (2/782)

The goal of this work was to determine the molecular basis for the induction of tumour vascularization and progression by injury. Magnetic resonance imaging (MRI) studies demonstrated that administration of wound fluid derived from cutaneous injuries in pigs reduced the lag for vascularization and initiation of growth of C6 glioma spheroids, implanted in nude mice, and accelerated tumour doubling time. The former effect can be attributed to the angiogenic capacity of wound fluid as detected in vivo by MRI, and in vitro in promoting endothelial cell proliferation. The latter effect, namely the induced rate of tumour growth, is consistent with the angiogenic activity of wound fluid as well as with the finding that wound fluid was directly mitogenic to the tumour cells, and accelerated growth of C6 glioma in spheroid culture. Of the multiple growth factors present in wound fluid, two key factors, heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) and platelet-derived growth factor (PDGF), were identified as the dominant mitogens for C6 glioma, and inhibition of their activity using specific neutralizing antibodies suppressed the mitogenic effect of wound fluid on DNA synthesis in C6 glioma. This study suggests that the stimulatory effect of injury on tumour progression can possibly be attenuated by therapeutic targeting directed against a limited number of specific growth factors.  (+info)

Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. (3/782)

Angiogenesis is essential for tumor progression and metastasis, however, the angiogenesis regulators that are biologically relevant for human melanoma are still unknown. In this study, we analyzed the expression of the potent angiogenic factor angiogenin (ANG) in human melanoma in vitro and in vivo. Four different human melanoma cell lines and two normal melanocytes were kept either under normoxic or hypoxic conditions. After 24 h of hypoxic culture conditions, ANG was up-regulated in the melanoma cell lines but not in normal melanocytes. Induction levels correlated with the metastatic potential of the cell lines. These data were confirmed by Northern blot analysis. In contrast, induction of vascular endothelial growth factor by hypoxia was equally strong in the examined highly aggressive melanoma cell lines and in one nonaggressive cell line. Other angiogenic factors tested as well as the melanoma growth stimulatory activity (Gro-alpha) showed no up-regulation. Thus, in the present study, hypoxia-induced up-regulation in melanoma cells was only observed for ANG and vascular endothelial growth factor. Immunohistochemical studies showed that 8 of 10 melanomas and all 15 metastases were positive for ANG, particularly in the vicinity of small vessels, whereas all benign nevi were negative. Reverse transcription-PCR detected only weak ANG mRNA in nevi but strong signals in primary melanomas and metastases. In conclusion, we demonstrate for the first time enhanced expression of ANG in highly metastatic cell lines as well as in melanomas and metastases in vivo, suggesting that ANG expression is associated with the metastatic potential.  (+info)

Effect of NO, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression. (4/782)

Exercise training results in several muscle adaptations, one of which is angiogenesis. Acutely, exercise leads to release of nitric oxide, prostacyclin (PGI2), and adenosine (A) in the skeletal muscles. In this paper, we asked whether any of these locally released vasodilators, as well as other known dilator prostaglandins (PGE1 and PGE2), have the potential to increase angiogenic growth factor gene expression in resting skeletal muscle. Seven groups of 5-7 female Wistar rats (age 8-12 wk, weight 250 +/- 10 g) were anesthetized and instrumented for carotid artery pressure and electromagnetic femoral artery blood flow measurement. One group acted as control while the other groups each received one of the following six agents by constant arterial infusion (dose in microg/min): A (200), nitroprusside (NP, 4.2), acetylcholine (100), PGE1 (1.9), PGE2 (1.7), and PGI2 (1.7). Each agent reduced peripheral vascular resistance to a similar extent (at least twofold). Densitometric mRNA/18S levels for vascular endothelial growth factor (VEGF) were increased 50% by NP and acetylcholine, were unaffected by PGE1 and PGE2, and were reduced 40% by PGI2. For basic fibroblast growth factor, only PGI2 had any effect, reducing mRNA/18S approximately 25%. For transforming growth factor-beta1, A, NP, and PGE1 led to reduced mRNA/18S, whereas PGE2 slightly increased mRNA/18S. For the principal putative angiogenic growth factor, VEGF, these data suggest that naturally secreted vasodilators in contracting skeletal muscle could be involved in regulation of gene expression, namely, nitric oxide in a positive and PGI2 in a negative direction.  (+info)

Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. (5/782)

To study vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) concentrations and their possible binders, serum from 22 non-pregnant and 55 pregnant women (15 at weeks 10-13; 40 at term), umbilical vein (n = 24) and artery (n = 13) and amniotic fluid (a pool of 50 at weeks 15-17; 11 at term) were assessed for VEGF and PlGF by an enzyme-linked immunosorbent assay. In amniotic fluid and maternal serum VEGF concentrations were <16 ng/ml and added VEGF was not recovered. VEGF was detected in serum from mothers post-partum (137 +/- 142 ng/l, mean +/- SD), umbilical artery (421 +/- 288 ng/l) and vein (502 +/- 339 ng/l) and non-pregnant controls (182 +/- 147 ng/l), and added VEGF was fully recovered. PlGF was detected in pregnancy serum (52 +/- 23 ng/l early pregnancy; 439 +/- 217 ng/l term pregnancy) and in amniotic fluid (early pregnancy 56 ng/l; term pregnancy 30 +/- 18 ng/l). PlGF was fully recovered in all samples. Gel filtration and isoelectric focusing revealed that in maternal serum and amniotic fluid [125I]VEGF was bound to a protein with an Mr of 400-700 kDa and an isoelectric point of approximately 8. This protein was not identical with alpha-2-macroglobulin (by an immunofluorometric assay), pregnancy zone protein or pregnancy associated plasma protein-A (by immunodiffusion). In conclusion, VEGF-binding activity is present in amniotic fluid and maternal blood. It disappears after delivery and is not detectable in fetal or non-pregnant serum.  (+info)

Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. (6/782)

We have compared the platelet number and the serum concentration of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and interleukin-6 (IL-6) in 80 blood samples of 50 patients with advanced cancer. We have also measured the mitogenic effect of patient sera on endothelial cells in vitro in order to estimate the biological activity of serum VEGF. Serum VEGF concentration correlated with platelet number (r = 0.61; P < 10(-4)). Serum IL-6 levels correlated with platelet count (r = 0.36; P < 10(-3)), with serum VEGF levels (r = 0.55; P < 10(-4)) and with the calculated load of VEGF per platelet (r = 0.4; P = 3 x 10(-4)). Patients with thrombocytosis had a median VEGF serum concentration which was 3.2 times higher (P < 10(-4)) and a median IL-6 serum level which was 5.8 times higher (P = 0.03) than in other patients. Serum bFGF did not show an association with any of the other parameters. Patient sera with high VEGF and bFGF content stimulated endothelial cell proliferation significantly more than other sera (P = 4 x 10(-3)). These results support the role of platelets in the storage of biologically active VEGF. Platelets seem to prevent circulating VEGF from inducing the development of new blood vessels except at sites where coagulation takes place. IL-6, besides its thrombopoietic effect, also seems to affect the amount of VEGF stored in the platelets. This is in accordance with the indirect angiogenic action of IL-6 reported previously. The interaction of IL-6 with the angiogenic pathways in cancer might explain the stimulation of tumour growth occasionally observed during IL-6 administration. It also conforms to the worse outcome associated with high IL-6 levels and with thrombocytosis in several tumour types and benign angiogenic diseases.  (+info)

Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action. (7/782)

Monocyte/macrophages play important roles in regulating tissue growth and angiogenesis through the controlled release of heparin-binding growth factors such as fibroblast growth factor (FGF), vascular endothelial growth factor, and heparin binding epidermal growth factor. The action of these potent growth mediators is known to be regulated by adsorption to heparan sulfate proteoglycans (HSPGs) on the surface and within the extracellular matrix of other neighboring cells, which respectively promote or restrict interactions with their signal-transducing receptors on target cells. Here we report on the nature of HSPGs inducibly expressed on the surface of macrophages that confer these cells with the capacity to regulate endogenous growth factor activity. We reveal that activated human macrophages express only a single major 48-kDa cell surface HSPG, syndecan-2 (fibroglycan) as the result of de novo RNA and protein synthesis. In addition, we demonstrate this macrophage HSPG selectively binds the macrophage-derived growth factors FGF-2, vascular endothelial growth factor and heparin binding EGF and can present FGF-2 in a form that transactivates receptor-bearing BaF32 cells. These results define a novel and unique proteoglycan profile for macrophages and imply a key role for syndecan-2 in the delivery of sequestered growth factors by inflammatory macrophages for productive binding to their appropriate target cells in vivo.  (+info)

Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. (8/782)

Neurofibromatosis type 1 is a common autosomal dominant disorder (incidence 1:3500) characterized by lesions that include neural crest derivatives such as Schwann cells and melanocytes. A critical event in the pathogenesis of neurofibromatosis type 1 is the heterozygous germ-line loss of the tumor suppressor gene NF1. Additional genetic and/or epigenetic events have been posited, including various alterations in growth factor expression. By in situ hybridization and immunohistochemistry, we demonstrate aberrant expression of the angiogenic and tumorigenic growth factor midkine in the skin of patients with neurofibromatosis type 1, but not normal individuals. We demonstrate that midkine expression is independent of the presence of neurofibromas, and thus appears to be associated with mutations in the NF1 gene. Furthermore, midkine-containing culture media is shown to stimulate the growth of human endothelial and neurofibroma-derived cells. In conclusion, we introduce the skin as a source of dysregulated growth factors in neurofibromatosis type 1, and suggest the further study of the angiogenic factor midkine in neurofibromatosis type 1 pathogenesis.  (+info)

*List of MeSH codes (D16)

... angiogenesis modulating agents MeSH D27.505.696.377.077.077 --- angiogenesis inducing agents MeSH D27.505.696.377.077.099 --- ... fertility agents, male MeSH D27.505.696.875.610 --- luteolytic agents MeSH D27.505.696.875.650 --- menstruation-inducing agents ... fertility agents, male MeSH D27.505.954.705.610 --- luteolytic agents MeSH D27.505.954.705.650 --- menstruation-inducing agents ... luteolytic agents MeSH D27.505.696.875.360.276.500 --- menstruation-inducing agents MeSH D27.505.696.875.360.276.727 --- sperm ...

*Semicarbazide-cadmium therapy

Cadmium may inhibit angiogenesis. As a stress agent, inducing apoptosis and blocking it, Cd can have both helpful and harmful ... Cadmium is a heavy metal and can also induce apoptosis. The first study in humans was an open pilot trial conducted in Russia ... Huff J; Lunn RM; Waalkes MP; Tomatis L; Infante PF (2007). "Cadmium-induced cancers in animals and in humans". Int J Occup ... Cadmium (metallotherapeutic drug, metal-based drug) can induce apoptosis (programmed tumor cell death) in various cell types. ...

*AEE788

It also inhibits VEGF-induced angiogenesis in a murine implant model. It has potential as an anticancer agent targeting ... It efficiently inhibited growth factor-induced EGFR and ErbB2 phosphorylation in tumors for >72 h, a phenomenon correlating ... growth factor-induced EGFR and ErbB2 phosphorylation was also efficiently inhibited with IC50s of 11 and 220 nM, respectively. ...

*Lenalidomide

In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, ... Lenalidomide is one of the novel drug agents used to treat multiple myeloma. It is a more potent molecular analog of ... In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulation. ... Compared to placebo, lenalidomide is effective at inducing a complete or "very good partial" response as well as improving ...

*MECOM

It has been observed that it not only induces apoptosis but can also inhibit the cell cycle, and has marked anti-angiogenesis ... Arsenic is a fairly ancient human therapeutic agent, however it has only recently returned to the forefront of cancer treatment ... TGF-β signaling induces transcription of the cyclin-dependent kinase (CDK) inhibitors p15Ink4B or p21Cip1, which, as a ... It has been hypothesized that it acts as a survival factor in tumor cell lines, preventing therapeutic-induced apoptosis and ...

*Survivin

Fulda S, Debatin KM (September 2004). "Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent ... whereby mice given the vaccine had less angiogenesis from the tumour challenge than the control mice that were not given any of ... In acquiring the humoral response to tumour antigens such as survivin, CD4+ T cells are activated to induce B cells to produce ... Although the details are not here, survivin was shown to also inhibit cytochrome c and caspase-8-induced activation of caspases ...

*Brivanib alaninate

... has been shown to inhibit HCC-induced proliferation and angiogenesis. Sorafenib has also been shown to provide a significant ... Based on these results, researchers concluded that this class of agents may be effective in the treatment of HCC. Brivanib is ... The trial drug is one of the first agents to demonstrate promising antitumor activity in advanced HCC patients treated with ... Doxorubicin (trade name Adriamycin; also known as hydroxydaunorubicin), the most widely used agent in HCC, has shown a 4% to ...

*ING4

"ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells". FEBS Letters. 570 ( ... "The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis". Nature. 428 (6980): 328-32. doi: ... and induce apoptosis. This protein contains a PHD-finger, which is a common motif in proteins involved in chromatin remodeling ... "The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis". Nature. 428 (6980): 328-32. doi: ...

*Copper in health

... is under investigation as an anti-angiogenic agent in pilot and clinical trials. The drug may inhibit tumor angiogenesis in ... The Cu-SPH complex was found to induce apoptosis in A549, H322 and H1299 lung cancer cells. A copper intrauterine device (IUD) ... Research has been ongoing over the past two decades to determine whether copper is a causative or a preventive agent of ... In humans, the liver is the primary organ of copper-induced toxicity. Other target organs include bone and the central nervous ...

*Margaret Reed Lewis

It has played a significant role in more recent tumor models used in metastatic and angiogenesis studies as it is a highly ... Some of Margaret Reed Lewis' research in the mechanics of cancer included myeloid infiltration and strangulation-induced ... one of the earliest tumors that could be transplanted and used to determine if a compound had potential as an anticancer agent ...

*Exisulind

... (tentative trade name Aptosyn) is an antineoplastic agent. It acts by inhibiting the enzyme cyclic guanosine ... Exisulind inhibits the enzyme cGMP-PDE, overexpressed in precancerous and cancerous colorectal cells, and induces apoptosis in ... Preclinical evidence suggests that exisulind also inhibits angiogenesis. Sulindac [No authors listed] (2004). "Exisulind: ... "Inhibition of Angiogenesis by Sulindac and its Sulfone Metabolite (FGN-1): a Potential Mechanism for Their Antineoplastic ...

*Taurolidine

... induces cancer cell death through a variety of mechanisms. Even now, all the antineoplastic pathways it employs are ... Taurolidine has been used as an antimicrobial agent in the clinical setting since the 1970s and thus far appears nontoxic. The ... It has been shown to enhance apoptosis, inhibit angiogenesis, reduce tumor adherence, downregulate pro-inflammatory cytokine ... Taurolidine is an antimicrobial agent used in an effort to prevent catheter infections. It however is not approved for this use ...

*Withaferin A

2004). "Withaferin A is a potent inhibitor of angiogenesis". Angiogenesis. 7 (2): 115-122. doi:10.1007/s10456-004-1026-3. PMID ... 3-azidoWA acts as a tumor suppressor by inducing Par-4, TIMP-1 and by reducing the levels of pAkt and pERK that are activated ... Therefore, withaferin A can be a potential therapeutic agent for the treatment of cervical cancer without major side effects. ... It can induce oxidative stress, alter gene expression, depolarize mitochondria. Withaferin A also down regulates VEGF gene ...

*MTOR inhibitors

Rapamycin has also shown to induce p53-independent apoptosis in certain types of cancer. Tumor angiogenesis rely on ... The response rate in solid tumors where rapalogs have been used as a single-agent therapy have been modest. Due to partial mTOR ... Rapamycin induces dephosphorylation of 4EBP1 as well, resulting in an increase in p27 and a decrease in cyclin D1 expression. ... mTORi-induced ILD often is asymptomatic (with ground glass abnormalities on chest CT) or mild symptomatic (with a non- ...

*Angiogenesis inhibitor

While the mechanisms of bleeding induced by anti-VEGF agents are complicated and not yet totally understood, the most accepted ... An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis ... See [1] and [2] Angiogenesis Inhibitors for Cancer - from The Angiogenesis Foundation, 23 June 2009 Angiogenesis Inhibitors for ... During tumor growth, the action of angiogenesis stimulators surpasses the control of angiogenesis inhibitors, allowing for ...

*Autocrine signalling

Another agent involved in autocrine cancer signaling is vascular endothelial growth factor (VEGF). VEGF, produced by carcinoma ... Paracrine signaling is a form of cell-cell communication in which a cell produces a signal to induce changes in nearby cells, ... Evidence from cell lines and primary breast cancer cultures in vitro". Angiogenesis. 8 (3): 197-204. doi:10.1007/s10456-005- ... An example of an autocrine agent is the cytokine interleukin-1 in monocytes. When interleukin-1 is produced in response to ...

*Germinal center B-cell like diffuse large B-cell lymphoma

Combining ABT-737 with second agents that inactivate Mcl-1 may reduce this effect. ABT-737 has demonstrated single-agent ... mTOR inhibitors lead to cell cycle arrest in the G1 phase and also inhibits tumor angiogenesis by reducing synthesis of VEGF. A ... A synthetic retinoid that induces apoptosis of cancer cells and acts synergistically with chemotherapeutic drugs by triggering ... Reduced susceptibility to apoptosis increases the resistance of cancer cells to radiation and cytotoxic agents. B-cell lymphoma ...

*Angiogenesis

McDougall, S.R, Anderson, A.R.A., Chaplain, M.A.J. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: ... the completed or ongoing clinical trials in which the FGF-1 protein is used as the therapeutic agent to stimulate angiogenesis ... Angiogenesis inhibitor can be endogenous or come from outside as drug or a dietary component. Angiogenesis may be a target for ... Sprouting angiogenesis was the first identified form of angiogenesis. It occurs in several well-characterized stages. First, ...

*Metastatic breast cancer

... inducing cell proliferation and release of cytokines(IL-6 and IL-8, potent bone resorptive agents) and stimulating bone ... Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Cancer Biology, Vol. 12, 2002: pp ... A macrobiotic diet is neither effective nor safe as it could hypothetically induce weight loss due to severe dietary ... Matrix metalloproteinases (MMPs) MMP-2 is the main metalloprotease secreted by breast-cancer cells or induced in the adjacent ...

*S1PR1

It was also shown in vivo that S1P synergizes with angiogenic factors such as FGF-2 and VEGF in inducing angiogenesis and ... Fingolimod, a drug which internalizes the receptor, is approved as a disease modifying agent in MS. There are other Sphingosine ... is strongly induced in endothelial cells during tumor angiogenesis and a siRNA against S1PR1 was able to inhibit angiogenesis ... Liu CH, Thangada S, Lee MJ, Van Brocklyn JR, Spiegel S, Hla T (April 1999). "Ligand-induced trafficking of the sphingosine-1- ...

*Discovery and development of tubulin inhibitors

Currently have been suggested few approaches in development of novel therapeutic agents with better properties Discovery agents ... They induce mitotic arrest in the G2-M phase of the cell cycle, resulting in apoptosis. Epothilone A and epothilone B exhibit ... It is known that some compounds can inhibit the formation of new blood vessels (inhibit the process of angiogenesis) or shut ... Play media Agents which act as inhibitors of tubulin, also act as inhibitors of cell division. Microtubule exists in a ...

*Hologenome theory of evolution

The causative agent, Vibrio AK-1, was present in 28 bleached O. patagonica examined, but absent from 24 healthy (unbleached) ... In 1989, Dodd reported mating preferences in Drosophila that were induced by diet. It has recently been demonstrated that when ... angiogenesis, vitamin synthesis, fiber breakdown, fat storage, supply of minerals from the soil, supply of organics, ... has been their claim that V. shiloi was misidentified as the causative agent of coral bleaching, and that its presence in ...

*Molybdenum

... disulfide (MoS2) is used as a solid lubricant and a high-pressure high-temperature (HPHT) antiwear agent. It forms ... It has also been found to have an inhibitory effect on angiogenesis, potentially by inhibiting the membrane translocation ... Copper reduction or deficiency can also be deliberately induced for therapeutic purposes by the compound ammonium ... antiangiogenic agent: Phase I study". Clinical Cancer Research. 6 (1): 1-10. PMID 10656425. Institute of Medicine (2000). " ...

*Transcatheter arterial chemoembolization

... resulting in a greater absorption of agents by the tumor cells. Tissue concentration of agents within the tumor is greater than ... TACE induces tumor necrosis in more than 50% of patients; the resulting necrosis releases cytokines and other inflammatory ... a vital component of tumor angiogenesis). All these events lead to a gradual shift in tumor blood supply from portal to ... Off-target delivery of embolic agents such as reflux into healthy surrounding tissue is a potential side effect that may cause ...

*Withanolide

... gene expression in Ehrlich ascites tumor cells and EAT cells induced angiogenesis on mouse peritoneal cavity. Withaferin A also ... Kinghorn, A. D.; Su, B. N.; Lee, D.; Gu, J. Q.; Pezzuto, J. M. (2003). "Cancer Chemopreventive Agents Discovered by Activity- ... 2004). "Withaferin a is a potent inhibitor of angiogenesis". Angiogenesis. 7 (2): 115-122. doi:10.1007/s10456-004-1026-3. PMID ... Ixocarpalactone A, isolated from the tomatillo (Physalis philadelphica), shows promise as an anti-tumor agent. Glotter, E. ( ...

*Prostaglandin-endoperoxide synthase 2

The lipoxins and epi-lipoxins are potent anti-inflammatory agents and may contribute to the overall activities of the two COX's ... Xiao G, Tsai AL, Palmer G, Boyar WC, Marshall PJ, Kulmacz RJ (February 1997). "Analysis of hydroperoxide-induced tyrosyl ... The overexpression of PTGS2 (COX-2) along with increased angiogenesis and SLC2A1 (GLUT-1) expression is significantly ... but also neutralized the changes of the retina and the choroid thickness caused by the injection of pro-inflammatory agents. ...
Definition of angiogenesis factor in the Legal Dictionary - by Free online English dictionary and encyclopedia. What is angiogenesis factor? Meaning of angiogenesis factor as a legal term. What does angiogenesis factor mean in law?
Synonyms for angiogenesis factor in Free Thesaurus. Antonyms for angiogenesis factor. 37 synonyms for factor: element, thing, point, part, cause, influence, item, aspect, circumstance, characteristic, consideration, component, determinant.... What are synonyms for angiogenesis factor?
Decreased collateral vessel formation in the diabetic peripheral limbs is characterised by abnormalities of the angiogenic response to ischemia. Hyperglycemia is known to activate protein kinase C (PKC) affecting the expression and activity of growth factors such as VEGF and PDGF. The present study investigates the role of PKCδ in diabetes-induced poor collateral vessel formation and inhibition of angiogenic factors expression and actions. Ischemic adductors muscles of diabetic Prkcd+/+ mice exhibited reduced blood reperfusion, vascular density and number of small vessels as compared to non-diabetic Prkcd+/+ mice. By contrast, diabetic Prkcd-/- mice showed significant increased blood flow, capillary density and number of capillaries. Although expression of various PKC isoforms were unchanged, activation of PKCδ was increased in diabetic Prkcd+/+ mice. VEGF and PDGF mRNA and protein expression were decreased in muscles of diabetic Prkcd+/+ mice and normalized in diabetic Prkcd-/- mice. ...
Diabetes is associated with the progression of vascular complications, such as peripheral arterial disease, and is a major risk factor for lower limb amputations (4). In the current study, we have demonstrated that activation of PKCδ diminishes the expression of VEGF and PDGF, two critical proangiogenic factors contributing to poor capillary formation and blood flow reperfusion of the ischemic limbs. In addition to reducing expression of VEGF and PDGF, phosphorylation of VEGF and PDGF receptors was abrogated in diabetic ischemic muscles compared with nondiabetic ischemic muscles. The inhibition of growth factor receptor phosphorylation was associated with the upregulation of SHP-1 expression, which has been reported to deactivate tyrosine kinase receptors such as VEGF and PDGF receptors. Overall, deletion of PKCδ prevents the reduction of VEGF and PDGF expression and re-establishes KDR/Flk-1 and PDGFR-β phosphorylation, favoring new capillary formation and blood flow reperfusion.. Wound ...
The ability to form new skeletal muscle capillaries in ischemic tissue is a major challenge. The concept that new blood vessels can grow to enhance tissue perfusion is now achieving widespread acceptance.20 Therapeutic angiogenesis is proposed as a complement or an alternative to surgical revascularization. To date, several proangiogenic factors, including VEGF and fibroblast growth factor, have been tested and have demonstrated convincing efficiency in acute and chronic experimental models21; however, clinical trials to test VEGF or fibroblast growth factor angiogenic therapy in coronary and peripheral artery diseases were disappointing because their effects were inconsistent.21,22 One of the explanations for the lack of efficiency of angiogenic therapy probably comes from the use of individual factors, whereas angiogenesis is known to involve a plethora of angiogenic factors.. On the basis of their previous data, Matsakas et al19 propose in this issue of Circulation Research a new and very ...
In July 1998, the Executive Board concluded discussions on the internal staff review and external evaluation of ESAF, and agreed on a number of proposals for strengthening the design and implementation of future ESAF-supported programs. This paper recalls the main conclusions from the reviews and reports on progress over the past year in implementing them.
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7-10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306). ...
Advanced St IIIB/IV NS-NSCLC p with ECOG 0-2 prospectively included and treated 1st-line with CP-Bev 6 cycles followed by Bev maintenance. Primary end-point: PFS; secondary end-points: OS, RR, toxicity. Ancillary study designed to investigate relationship between angiogenic mediators, response and outcomes. Ethical approval and informed consent for collecting peripheral blood samples and associated clinical data. Samples collected before treatment (basal) and at response evaluation (post). DNA obtained from leukocyte fraction. SNPs of angiogenic genes genotyped by PCR. Plasma levels of VEGFA and VEGFR2 determined by ELISA. Response RECIST.1 and toxicity CTCAEv.1. ...
This review tries to answer two main questions: (i) What are the neurophysiological underpinnings of the most commonly selected cluster descriptors which define the qualitative dimension of dyspnea in patients? (ii) How do mechanical constraints affe
Hypoxia has a profound influence on progression and metastasis of malignant tumors. In the present report, we used the oligonucleotide microarray technique to identify new hypoxia-inducible genes in malignant melanoma with a special emphasis on angiogenesis factors. A commercially available Affymetrix gene chip system was used to analyze five melanoma cell lines of different aggressiveness. A total of 160 hypoxia-inducible genes were identified, clustering in four different functional clusters. In search of putative angiogenesis and tumor progression factors within these clusters, Cyr61, a recently discovered angiogenesis factor, was identified. Cyr61 was hypoxia-inducible in low aggressive melanoma cells; however, it showed constitutive high expression in highly aggressive melanoma cells. Further analyses of transcriptional mechanisms underlying Cyr61 gene expression under hypoxia demonstrated that an AP-1 binding motif within the Cyr61 promoter plays a central role in the hypoxic regulation of ...
Angiogenesis is essential for tumor growth and metastasis and depends on the production of angiogenic factors by host and/or tumor cells. The role of angiogenesis and angiogenic factor expression in intestinal- and diffuse-type gastric cancer are undefined. Archival specimens of 51 intestinal-type and 38 diffuse-type human gastric carcinomas were examined for tumor vessel counts, angiogenic factor expression, and the presence or absence of angiogenic factor receptors on tumor endothelium using antibodies against vascular endothelial growth factor (VEGF) and its receptors (KDR and flt-1), basic fibroblast growth factor (bFGF) and its receptors (bek and flg), and factor VIII (endothelial cells). Vessel count and VEGF and bFGF expression were higher in intestinal-type than in diffuse-type gastric cancers (P = 0.01, P , 0.001, and P , 0.001, respectively). Similarly, vessel count and VEGF expression were higher in patients with liver metastasis than in patients with peritoneal dissemination (P = ...
VG5Q functions as an angiogenic factor in promoting angiogenesis and suppression of VG5Q expression inhibits vessel formation. Angiogenic factors are…
This is the first report that Del-1 is expressed in adult animals in response to ischemia and that it plays an important role in adult angiogenesis. The protein encoded by Del-1 plays a critical role in embryonic vascular development. However, at the time of birth, the gene becomes quiescent, and Del-1 is no longer expressed in normal adult tissues.. In the embryo, Del-1 is expressed by endothelial progenitor cells and is secreted into the extracellular matrix.1 Del-1 supports adherence and migration of endothelial cells, mediated largely through the αvβ3 integrin receptor. Accumulating evidence indicates that angiogenesis requires signaling through both growth factor and integrin signaling pathways. Endothelial cells deprived of either influence will undergo programmed cell death.12 Indeed, in the chick CAM assay, antibodies directed against αvβ3 suppress Del-1-induced angiogenesis.13 A mutant form of Del-1, when the RGD motif has been altered (RGD→RAD), also disrupts angiogenesis in this ...
Health, ...The beneficial effects of anti-angiogenesis drugs in the treatment of ... Our findings suggest that antiangiogenesis therapy can increase patie...Cediranib inhibits the potent angiogenesis factor VEGF which is known... We frequently see beneficial effects from drugs in patients without f...,Angiogenesis,inhibitor,improves,brain,tumor,survival,by,reducing,edema,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Recombinant purified Human Angiogenin protein W. blot +ve control \ ANGN12-C for more molecular products just contact us
Therapeutic Angiogenesis By Yukihito Higashi, Toyoaki Murohara English | PDF | 2017 | 262 Pages | ISBN : 9811027439 | 7 MB http://mir.cr/0LE45NIO
Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability, it may play a role in stimulating Vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant rat VEGF produced in E. coli is a double, non-glycosylated, polypeptide chain of 165 amino acids ...
Imaging of growing vasculature and quantitative measurement of perfusion are very important in the assessment of clinical efficacy of angiogenic therapies. Strong vascular growth during therapeutic angiogenesis by overexpression of VEGF family members involving abundant capillary enlargement leading to capillary arterialization (6) and increased vascular permeability interferes with many current vascular imaging and perfusion measurement techniques. We found in this study that real-time CPS ultrasound imaging is a feasible and accurate perfusion measurement method after GT for therapeutic vascular growth in peripheral muscles of small and large experimental animals.. None of the current noninvasive perfusion measurement techniques, such as DCE-MRI, CT, SPECT, PET, laser Doppler, optical imaging methods, and previous ultrasound techniques, can provide simultaneous capillary level imaging at a high frame-rate, good penetration, efficient contrast agent separation from background tissue, and a ...
The authors make gelatin-PEG tyramine gels (GPT gels) that they functionalize with a SVVYGLR peptide. The SVVYGLR sequence, often found near an RGD sequence in different types of ECM, has been shown to improve adhesion, migration, and tube formation of endothelial cells. Crosslinking and bioconjugation of the peptide sequence is done using a horseradish-peroxide (HRP) mediated tyrosine radical dimerization. The authors then demonstrate that human umbilical endothelial cells have better attachment and proliferation on gels containing the SVVYGLR sequence than on gels containing just RGD. They also look at the vascularization of gels subcutaneously injected into rats ...
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, plays a decisive role for the rapid growth of avian follicles. Compared to mammals, few data on the angiogenesis in the avian ovary are available. However, whereas several pro-angiogenic factors in the avian ovary have been recently studied in detail, little information is available on the localization of anti-angiogenic factors. The aim of this study was to determine the localization and possible function of the anti-angiogenic factor thrombospondin-1 (TSP-1) and its receptor CD36 in the ovary of the ostrich using immunohistochemistry and to correlate the results with ultrastructural data ...
Extensive studies of the genetic changes that accompany cancer development and progression have made it increasingly clear that cancer development is a highly complex process involving multiple factors or genes. Multiple genetic changes linked to glioma malignancy have been identified. The tumor suppressor gene p53 is mutated frequently in all grades of gliomas (32) . Several growth factors and growth factor receptors are frequently overexpressed in gliomas (33, 34, 35) . Among these, VEGF, an important angiogenesis factor, is highly expressed in glioblastomas (31) . On the basis of this and other evidence, it is believed that genetic and molecular alterations fundamentally change the signal transduction pathways through which cells interact with their surroundings and respond to environmental cues.. These genetic alterations do not necessarily happen simultaneously in each cancer patient, and different genetic changes may have different impacts on the cells. Some of the genetic changes may have ...
Angiogenesis (angiogenesis) -- the growth of new blood vessels -- is an important natural process occurring in the body, both in health and in disease. Angiogenesis occurs in the healthy body for healing wounds and for restoring blood flow to tissues after injury or insult. In females, angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and fetus ...
Synonyms for Angiogenin in Free Thesaurus. Antonyms for Angiogenin. 1 synonym for ANG: Air National Guard. What are synonyms for Angiogenin?
A large population of patients suffering from advanced coronary artery disease and chronic myocardial ischemia cannot be adequately managed by a combination of antianginal medication and angioplasty or coronary artery bypass surgery. Therefore, therapeutic stimulation of vascular growth in the management of chronic myocardial ischemia seems to be a useful strategy in treating such patients. A number of recent clinical trials have examined the role of therapeutic administration of molecular regulators of blood vessel growth to promote vascular development to treat ischemic heart disease (1). The patients eligible for these therapeutic angiogenic trials often have underlying ischemic but viable "hibernating" myocardium, characterized by persistent myocardial dysfunction in the presence of resting hypoperfusion or chronic myocardial stunning due to repetitive episodes of stress-induced ischemia in myocardial regions with severely impaired coronary flow reserve. Fallavollita et al. (2) have ...
Peripheral ischemia as a result of occlusive vascular disease is a widespread problem in patients over the age of 65. Angiogenic therapies that can induce microvascular growth have great potential for providing a long lasting solution for patients with ischemia and would provide and an appealing alternative to surgical
A novel angiogenic composition obtained from the omentum is provided which acts as a potent and effective factor for blood perfusion enhancement and for the development of new blood vessels in an organized structural network in living tissues. The angiogenic composition is a lipid or lipids, essentially protein-free as extracted from the omentum using organic solvents. This composition can then be injected to target to a site where new blood vessel formation, or blood perfusion enhancement is required. This material can be used to heal various damaged tissues including bone and heart.
The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.
Figure 1. Schematic representation of secreted and membrane-bound MMPs and related ADAMs and ADAMTSs involved in angiogenesis. The proteins have various domains with specific functions in common. Key regulators of angiogenesis are indicated by the yellow squares. MT-MMP-1, -2, -3, and probably -5 enhance angiogenesis by their pericellular action (see Figure 4). Similarly MMP-2 and MMP-9 stimulate angiogenesis and can act pericellular by binding to membrane-anchored proteins. Pro-MMP-23 has a transmembrane domain, but this is removed during activation of the protease, making the active enzyme a soluble MMP. Part of the ADAM family members has proteolytic activity, of which ADAM-10,-15, and -17 are known to affect angiogenesis. ADAMTS-1 and the related ADAMTS-4 and -8 also can affect angiogenesis mainly via their thrombospondin (TSP) domains. The MMPs and MT-MMPs are depicted according to Sato50 with some modifications. ...
Neovascularization is a limiting factor in tumor growth and progression. It is well known that changes in the tumor microenvironment, such as hypoxia and glucose deprivation (GD), can induce VEGF production. However, the mechanism linking GD to tumor growth and angiogenesis is unclear. We hypothesize that GD induces the angiogenic switch in tumors through activation of the unfolded protein response (UPR). We report that UPR activation in human tumors results in elevated expression of proangiogenic mediators and a concomitant decrease in angiogenesis inhibitors. cDNA microarray results showed that GD-induced UPR activation promoted upregulation of a number of proangiogenic mediators (VEGF, FGF2, IL6, etc.) and downregulation of several angiogenic inhibitors (THBS1, CXCL14 and CXCL10). In vitro studies revealed that partially blocking UPR signaling by silencing PERK or ATF4 significantly reduced the production of angiogenesis mediators induced by GD. However, suppressing the alpha subunit of ...
The present study demonstrated the validity and superiority of CD105 as a marker of angiogenesis in NSCLC; the CD105-IMVD was more closely correlated with the expression of VEGF than the CD34-IMVD. Kumar et al. (11 , 13 , 15, 16, 17, 18) and others have demonstrated that anti-CD105 antibodies preferentially react with activated ECs in tissues participating in angiogenesis, such as tumor tissues, and that antibodies against pan-ECs, such as anti-CD34 antibodies, react with normal vessels, as well as activated vessels. According to the hypothesis, we tried to define the CD34-IMVD-CD105-IMVD as the baseline IMVD. As a result, the baseline IMVD proved not at all to be correlated with VEGF expression, suggesting the baseline IMVD was not a measurement of angiogenesis but a measurement of vessels just trapped within tumor tissues. Of course, it should be noted that angiogenesis is not influenced only by VEGF but also other angiogenic factors and antiangiogenic factors, such as angiostatin. Comparative ...
The views presented here are those of the author and are not to be construed as official or reflecting the views of the Uniformed Services University of the Health Sciences, the Department of Defense or the U.S. Government ...
Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis may take place in two ways - endothelial sprouting or non-sprouting (intussusceptive).
Phenotypical signature of pro-angiogenic TEM.(A) In vivo corneal vascularization assay to assess the pro-angiogenic activity of TEM isolated from peripheral blo
Sigma-Aldrich offers abstracts and full-text articles by [Maosheng Zhan, Yumiko Hori, Naoki Wada, Jun-Ichiro Ikeda, Yuuki Hata, Keigo Osuga, Eiichi Morii].
The worlds first wiki where authorship really matters. Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts.
A concoction that meddles with the signs to structure fresh recruits vessels is alluded to as an angiogenesis inhibitor. Researchers have examined the impa..
The term therapeutic angiogenesis is a concept that had first been introduced by the German gynecologist Michael Höckel in 1989 [1]. The idea was to induce capillary growth in order to improve regional tissue perfusion and to improve tissue viability following surgery. Much has happened in the field since then. Major angiogenesis factors and their receptors have been identified, isolated, cloned and characterized. Preclinical data has accumulated which clearly proves the concept that angiogenic growth factors are capable of inducing vascular and collateral growth. This had been shown for VEGF-A, for bFGF as well as for other growth factors [2]. Proof of concept had been achieved in animal models of both peripheral ischemia and regional myocardial ischemia in the early 1990s.. The concept of collateral artery growth has been modified by the introduction of the term "arteriogenesis", which describes the growth of mature arteries [3] of large caliber. The prevailing concept is that these mature ...
The data of the present study demonstrate that S1P can induce eNOS phosphorylation and NO production by way of the PI3K/Akt pathway in cultured ECs and that NO plays a critical role in S1P-induced angiogenesis in vitro and in vivo. Platelets contain many angiogenic factors, and the angiogenic activity of those released by platelets plays an important role in initiating angiogenesis in injured tissue, especially in wound healing and tumor angiogenesis. It seems likely that S1P, which is known to be abundantly stored in platelets and released on their activation,17 may contribute to platelet-induced angiogenesis in wound repair, because it was demonstrated that S1P is the major EC chemoattractant released into serum by platelets during blood clotting.18 Therefore, it is suggested that the angiogenic activity of S1P may account for the important role of platelet interaction with ECs in angiogenesis at sites of injury. Interestingly, previous studies have demonstrated the crucial role of NO in wound ...
Angiogenesis, the process of new blood vessel formation from existing vessels, plays an important role in normal physiology (Tonnesen et al., 2000), as well as in many pathological conditions including cancer (Folkman, 1971; Papetti and Herman, 2002), macular degeneration (Ahmad et al., 2011), and various vascular diseases (Khurana et al., 2005). Strikingly, increased angiogenesis is observed in many types of human cancers (Bergers and Benjamin, 2003; Dvorak, 2003), whereas angiogenesis is decreased in age-associated vascular diseases (Ungvari et al., 2010). Therefore, diseases that are associated with increased angiogenesis, such as human cancers, can be treated by inhibiting angiogenesis (Folkman, 2007). In contrast, stimulation of angiogenesis could be beneficial in the treatment of coronary artery disease and other vascular diseases characterized by insufficient blood flow to target organs as a result of blocked or damaged blood vessels (Khan et al., 2002; Al Sabti, 2007). Many factors that ...
The sprouting and development of blood vessels affects numerous processes in the body, and excessive or insufficient angiogenesis can exacerbate a variety of disease states. Therefore, precise regulation of angiogenesis is crucial to an organisms survival. Studies knocking down Dicer and Drosha implicated miRNAs in regulation of angiogenesis, and subsequent studies revealed roles for miR-126, the miR17~92 cluster, miR378, miR-210, miR-296, and others in various settings such as neoangiogenesis in response to injury, developmental angiogenesis, and tumor angiogenesis. (1, 5). Over the past year, significant progress has been made in discovering which miRNAs drive this process in both normal physiology and in various disease states. Due to these studies and others, a clearer picture of the miRNA network governing angiogenesis is starting to emerge. This review spans some of the most significant recent discoveries that have contributed to our understanding of "angiomiR" function in vascular ...
The sprouting and development of blood vessels affects numerous processes in the body, and excessive or insufficient angiogenesis can exacerbate a variety of disease states. Therefore, precise regulation of angiogenesis is crucial to an organisms survival. Studies knocking down Dicer and Drosha implicated miRNAs in regulation of angiogenesis, and subsequent studies revealed roles for miR-126, the miR17~92 cluster, miR378, miR-210, miR-296, and others in various settings such as neoangiogenesis in response to injury, developmental angiogenesis, and tumor angiogenesis. (1, 5). Over the past year, significant progress has been made in discovering which miRNAs drive this process in both normal physiology and in various disease states. Due to these studies and others, a clearer picture of the miRNA network governing angiogenesis is starting to emerge. This review spans some of the most significant recent discoveries that have contributed to our understanding of "angiomiR" function in vascular ...
Tumors cells need a rich blood supply in order to grow and metastasize. Angiogenesis (Angio-blood, genesis-creation) is the process by which new blood vessels, called capillaries are formed. Capillaries are lined with endothelial cells. Normal angiogenesis occurs under very tight physiological regulation when stimulators and inhibitors work in balance with each other. Normally the proliferation…
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.
Sigma-Aldrich offers abstracts and full-text articles by [M C Ramello, J Tosello Boari, F P Canale, H A Mena, S Negrotto, B Gastman, A Gruppi, E V Acosta Rodríguez, C L Montes].
Sierra-Honigmann, M.R., Nath, A.K., Murakami, C., Garcia-Cardena, G, Papapetropoulos, A., Sessa, W.C., Madge, L.A., Schechner, J.S., Schwabb, M.B., Polverini, P.J., and Flores-Riveros, J.R. (1998) Biological action of leptin as an angiogenic factor. Science 281:1683-1686 ...
购买我们的重组人PLGF蛋白。Ab84148为全长蛋白,在HEK 293细胞中生产并经过SDS-PAGE实验验证。Abcam提供免费的实验方案,操作技巧及专业的支持。中国80%以上现货。
Definition of angiogenic gene therapy in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is angiogenic gene therapy? Meaning of angiogenic gene therapy as a finance term. What does angiogenic gene therapy mean in finance?
Coordination between the vascular system and forming organs is essential for proper embryonic development. The vasculature expands by sprouting angiogenesis, during which tip cells form filopodia that incorporate into capillary loops. Although several molecules, such as vascular endothelial growth factor A (Vegfa), are known to induce sprouting, the mechanism that terminates this process to ensure neovessel stability is still unknown. Sphingosine-1-phosphate receptor 1 (S1P1) has been shown to mediate interaction between endothelial and mural cells during vascular maturation. In vitro studies have identified S1P1 as a pro-angiogenic factor. Here, we show that S1P1 acts as an endothelial cell (EC)-autonomous negative regulator of sprouting angiogenesis during vascular development. Severe aberrations in vessel size and excessive sprouting found in limbs of S1P1-null mouse embryos before vessel maturation imply a previously unknown, mural cell-independent role for S1P1 as an anti-angiogenic factor. ...
Both defective and persistent angiogenesis are linked to pathological situations in the adult. Compounds able to modulate angiogenesis have a potential value for the treatment of such pathologies. Several small molecules present in the diet have been shown to have modulatory effects on angiogenesis. This review presents the current state of knowledge on the potential modulatory roles of dietary proteins on angiogenesis. There is currently limited available information on the topic. Milk contains at least three proteins for which modulatory effects on angiogenesis have been previously demonstrated. On the other hand, there is some scarce information on the potential of dietary lectins, edible plant proteins and high protein diets to modulate angiogenesis.
Therapeutic angiogenesis remains a worthy but somewhat elusive clinical goal. Attempts to increase blood flow to ischemic tissue have included a variety of physical and biological approaches. A growing understanding of the cells and proteins involved in vessel sprouting and maturation led to a number of genetic approaches aimed at promoting angiogenesis in ischemic myocardium and skeletal muscle. In spite of several strategies undergoing testing in clinical trials, the delivery of vectors encoding for single growth factors has not yet shown clinical efficacy. In response to these challenges, a number of groups have aimed to provide multiple angiogenic factors for ischemic tissue. These approaches include gene transfer of transcription factors that regulate multiple angiogenic peptides (such as hypoxia inducible factor-1 ) or transplantation of cells capable of providing a regulated source of secreted growth factors and cytokines. A potential advantage of delivered cells is that they may also directly
Mathematical Institute, Leiden University, The Netherlands. Title: Stigmergy in blood vessel growth: how indirect mechanical and chemical signaling, via the extra-cellular matrix, can coordinate collective cell behavior. Abstract: Angiogenesis, the formation of new blood vessels sprouting from existing vessel, occurs in several situations like wound healing, tissue remodeling, and near growing tumors. Under hypoxic conditions, tumor cells secrete growth factors, including VEGF. VEGF activates endothelial cells (ECs) in nearby vessels, leading to the migration of ECs out of the vessel and the formation of growing sprouts. A key process in angiogenesis is cellular self-organization, and previous modeling studies have identified mechanisms for producing networks and sprouts. Most theoretical studies of cellular self-organization during angiogenesis have ignored the interactions of ECs with the extra-cellular matrix (ECM), the jelly or hard materials that cells live in. Apart from providing ...
Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
The larger number of T-lymphocytes in the periphery of vitiligo lesions and their association with angiogenesis are reported. The objective of this study was to investigate angiogenesis, VEGF and mast
Angiogenesis (also known as neovascularization) is the generation of new blood vessels from pre-existing vasculature. It is a normal process in growth and development and is required for the formation of arteries, veins, and capillaries in an embryo. Proliferation of new blood vessels also takes place in adults and is essential for the repair or regeneration of tissue during wound healing ...
Angiogenesis is the creation of new blood vessels. The body creates small blood vessels called "collaterals" to help compensate for reduced blood flow.. ...
Hybrigenics was developing nanomolar selective compounds that target tumour angiogenesis for the treatment of cancer. Several antikinase inhibitor compounds
Gentaur molecular products has all kinds of products like :search , Signosis 2011 \ Human Angiogenesis ELISA Strip I for Profiling 8 Cytokines \ EA-1011 for more molecular products just contact us
The laboratory of Masanobu Komatsu, Ph.D., studies the regulation of blood vessel growth and remodeling to aid the treatment of cancer and heart disease
Angiogenesis is an essential process whereby new blood vessels are formed from pre-existing vessels and occurs under both normal and pathophysiological conditions. growth element receptor 1 (sVEGFR-1). Therefore, FoxC1 appears to control angiogenesis by regulating two unique and opposing mechanisms; if so, vascular development could be identified, at least in part, Elvitegravir by a competitive balance between pro-angiogenic and anti-angiogenic FoxC1-controlled pathways. With this review, we describe the mechanisms by which FoxC1 regulates vessel growth and discuss how these observations could contribute to a more total understanding of the part of FoxC1 in pathological angiogenesis. Intro Under both physiological and pathological conditions, new blood vessels are created from pre-existing vessels through a process called angiogenesis, which is definitely exactly controlled by the balance between pro-angiogenic and anti-angiogenic factors. Vascular endothelial growth element (VEGF)-A is perhaps ...
Substance P (SP) is a therapeutic peptide that has been widely used to induce angiogenesis and tissue regeneration. However, its therapeutic efficacy is often limited due to rapid degradation in vivo and a short half-life (1 min) after systemic administration. In the present study, we chemically modified SP with polyethylene glycol (PEG) to generate long-lasting formulations with increased stability and extended retention time in vivo and evaluated their ability to enhance therapeutic angiogenesis. Compared to the unmodified SP, PEGylated SP (PEG-SP) exhibited significantly increased half-life in vivo ('360-fold increase in normal mouse and (similar to)120-fold increase in diabetic mouse). Systemic injection of PEG SP led to a marked increase in therapeutic efficacy and angiogenesis in diabetic hindlimb ischemia, as evident from the remarkable improvement in salvage of ischemic limb and recovery of blood perfusion in diabetic mice with limb ischemia. These formulations increased endogenous ...
First we focused on the function of the TMD23 portion of rTM used for treatment. Previously, domain 23 has been considered an angiogenic factor,30 promoting mouse cutaneous wound healing through modulating angiogenesis at the wound site.38,39 Thus, to determine whether the anti-inflammatory effects we observed were because of a possible angiogenic effect of rTM containing domains 23, classic angiogenic molecule VEGF, and its R1 and R2 receptor proteins, were measured in the infected cornea in rTM-treated and control mice. The VEGF protein did not differ at either 3 or 5 days p.i., while the level of R1 was slightly elevated at 3 and reduced at 5 days; R2 levels were unchanged at 3 and reduced at 5 days p.i. after rTM treatment. Because numerous molecules are angiogenic and it would be impossible to test all of them, India ink35,36 was used to globally assess the angiogenic potential of the 23 domain contained in rTM. Visual, followed by statistical analysis of these data showed no difference ...
Nonetheless, EPC subpopulations may well display different angiogenic properties. As highlighted in this issue of the Journal, Sieveking et al. (7) provide new insights from a novel human angiogenesis assay, showing that although fresh EPCs can be directly incorporated into the endothelial monolayer, other endothelial-like cells from CFU-ECs, when transplanted into ischemic tissues, they promote angiogenesis and are found around the neovasculature but are not incorporated within it (7). These spindle-like cells appear to possess a relatively low proliferative capacity and a low ability to express mature endothelial proteins (8). The exact mechanisms of their effects on cardiovascular health are still poorly understood, with no evidence that these cells are a major source of mature endothelial cells.. These important observations may make some previous study results difficult to interpret, given that more than 1 kind of cell with angiogenic properties exist. This raises some controversy with ...
Blood vessel formation. Artwork showing malignant (cancerous) tumour cells promoting the formation of new blood vessels, a process known as angiogenesis. The tumour cells release angiogenic growth factor proteins that bind to endothelial cells in nearby blood vessels and encourage the growth of new blood vessels from the existing ones. These blood vessels provide the tumour with oxygen and nutrients. - Stock Image C026/8534
Introduction: We have previously shown that treatment with epidermacan a novel stem cell derived paracrine factor promoted angiogenesis in vitro accompanied with an increase in angiogenic miRNA expression. Here, we identified novel microRNAs regulated by epidermacan and validated their importance in modulating the epidermacan angiogenic effects in vitro and in vivo.. Methods and Results: Increased levels of pro-angiogenic miRNAs such as miR-10b, miR-21 and miR-424 were discovered in MicroRNA profiling of HUVEC cells treated with epidermacan and then confirmed by qRT-PCR. We also identified miR-874, a relatively unknown miRNA but for its role as a tumor suppressor. Investigation of the downstream microRNA/gene networks revealed that epidermacan regulated known angiogenic genes such as VEGFC, TBX1, HIF-1a and NRP1. Importantly, treatment with epidermacan decreased the levels of HoxD10, a known target of miR-10b in thrombin induced angiogenesis. Inhibition of miR-10b or miR-874 via anti-miR ...
CANSSUFIVE is also based on the technology platform of angiogenesis screening assays. These unique assays screen for angiogenesis which is the process of new blood vessels formation from pre-existing blood vessels. Angiogenesis is an essential natural process in the body for healing and reproduction. The human body produces a precise balance of growth and inhibitory factors in healthy tissues to control angiogenesis. When this balance is altered, the result is either excessive or insufficient angiogenesis. The abnormal angiogenesis is a common denominator in many conditions including cancer, Alzheimers disease, diabetic blindness, wet age related macula degeneration, obesity and rheumatoid arthritis ...
In a novel study, University of North Carolina and the College of Arts and Sciences scientists have identified a novel mechanism that triggers blood vessel growth.
... covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition.
Blood vessel growth; Sprouting angiogenesis; Computational modeling; Particle-continuum coupling; 3D; Matrix-bound VEGF; Extracellular matrix; ...
A family of structurally-related angiogenic proteins of approximately 70 kDa in size. They have high specificity for members of the TIE RECEPTOR FAMILY ...
We investigated whether the angiogenic profile, which is based on the local expression and systemic levels of angiogenic growth factors (VEGF, Ang-1, Ang-2, and the corresponding receptors), differs between rheumatoid arthritis (RA) and osteoarthritis (OA) patients. We determined the expression of VEGF, Ang-1, and Ang-2 together with its receptors (VEGFR-1/-2 ...
Rat polyclonal antibody raised against recombinant Vegfb. Recombinant protein corresponding to mouse Vegfb. (PAB13528) - Products - Abnova
1UN4: Crystallographic Studies on Structural Features that Determine the Enzymatic Specificity and Potency of Human Angiogenin: Thr44, Thr80 and Residues 38-41
Cutaneous brest cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition ...
By Sayan Chakraborty, Senior Researcher at the Institute of Molecular and Cell Biology, A-STAR, Singapore In our hectic modern lifestyle, we are constantly subjected to stress of many kinds including the stress experienced by our body from weight-gain. From the physiological perspective, these symptoms are managed by signalling molecules present in the body that control…
Human VEGFB full-length ORF ( AAH08818.1, 1 a.a. - 207 a.a.) recombinant protein with GST-tag at N-terminal. (H00007423-P01) - Products - Abnova
Angiopoietin 1兔多克隆抗体(ab94684)可与小鼠, 人样本反应并经WB, IHC实验严格验证并得到1个独立的用户反馈。所有产品均提供质保服务,中国75%以上现货。
Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents. The various natural angiogenesis inhibitors identified so far affect neovascularization by different mechanisms of action. Thrombospondin-1 (TSP-1) is a matricellular modular glycoprotein that acts as a powerful endogenous inhibitor of angiogenesis. It acts both indirectly, by sequestering angiogenic growth factors and effectors in the extracellular environment, and directly, by inducing an antiangiogenic program in endothelial cells following engagement of specific receptors including CD36, CD47, integrins and proteoglycans (all involved in angiogenesis ). In view of its central, multifaceted role in angiogenesis, TSP-1 has served as a source of antiangiogenic tools, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies, and agents that up-regulate TSP
Angiopoietin 1 and Angiopoietin 2 are important for development of the endothelium, by regulating tyrosine phosphorylation of the membrane receptor Tie 2. Angiopoietin 2 is only 60% homologous with Angiopoietin 1. Angiopoietin-2 is a naturally occurring antagonist of angiopoietin-1 that competes for binding to the TIE2 receptor and blocks ANGPT1-induced TIE2 autophosphorylation. Angiopoietin 1 binding to Tie 2 causes phosphorylation of the receptor. Angiopoietin 2 competes for this binding, and thus blocks receptor phosphorylation. Angiopoietin 2 expression occurs at sites of vascular remodelling: dorsal aorta and major aortic branches, ovary, placenta and uterus. ...
Angiogenesis, the summation of multiple cellular and biologic processes culminating in the propagation of blood vessels, has been the subject of extensive examination in the context of tumor biology over the past 4 decades since it was first proposed by Judah Folkman in 1971 (1). Solid tumor growth and progression is dependent on tumor-associated angiogenesis. Tumor expression and circulating levels of angiogenic factors have been correlated with aggressive tumor growth, predilection for metastasis, and prognosis in a wide array of solid tumors, including lung cancer (2-4). Although many putative regulators of angiogenesis have been identified, 2 secreted factors, VEGF and basic fibroblast growth factor (bFGF), have been, in particular, strongly implicated in tumor-associated angiogenesis (5). VEGF and bFGF interact with distinct families of tyrosine kinase receptors (RTK) on the surface of endothelial cells and activate multiple downstream signaling pathways. Together, these pathways promote ...
294629575 - EP 1086212 A2 2001-03-28 - METHOD AND REAGENTS FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO MOLECULES INVOLVED IN ANGIOGENIC RESPONSES - [origin: WO9950403A2] Nucleic acid molecule which modulate the synthesis, expression and/or stability of an mRNA encoding for angiogenic factors selected from aryl hydrocarbon nuclear transport (ARNT), intergrin subunit beta 3 ( beta 3), integrin subunit alpha 6 ( alpha 6) and tie - 2 RNA. This invention further provides a treatment for indications related to angiogenesis using the nucleic acid molecules.[origin: WO9950403A2] Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding for angiogenic factors selected from aryl hydrocarbon nuclear transport (ARNT), intergrin subunit beta 3 ( beta 3), integrin subunit alpha 6 ( alpha 6) and tie - 2RNA. This invention further provides a treatment for indications related to angiogenesis using the nucleic acid molecules.[origin: WO9950403A2] Nucleic acid molecule
On the left: blood vessel formation that resulted from normal galectin-3 function. On the right: reduced blood vessel formation when galectin-3 was depleted.. (Image courtesy of Tufts University). Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice. These discoveries, published online August 16 in The Journal of Experimental Medicine, may lead to novel treatments for diseases caused by excessive angiogenesis, including age-related macular degeneration, cancer, and diabetes.. When the body needs to expand its network of blood vessels, cells release molecular signals called growth factors that prompt angiogenesis. While this process is key for normal growth, development, and wound healing, it can be harmful when blood vessels supply tumors or other diseased tissue, or when excessive blood vessel growth encroaches on surrounding tissues.. A growing body of research indicates that a protein called galectin-3 promotes angiogenesis, indicating ...
Low expressions of angiogenic growth factors delay the healing of diabetic wounds by interfering with the process of blood vessel formation. Heparin mimetic peptide nanofibers can bind to and enhance production and activity ...
Blog on VEGFB elisa kit product: The Bovine VEGFB n/a (Catalog #MBS055549) is an ELISA Kit and is intended for research purposes only. The...
1B1E: Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.
Commander Angiopoietin 2 kit ELISA pour beaucoup de réactivité. Poulet, Boeuf (Vache), Chien et plus. Comparez Angiopoietin 2 kit ELISA et trouvez le bon produit chez anticorps-enligne.fr.
Rheumatoid arthritis (RA) is characterized by exuberant angiogenesis and leukocyte infiltration in the synovial tissue (ST). We have shown that the soluble adhe...
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth). Read More » ...
The bacteria that live in your intestines change the way that blood vessels form inside your gut. New research, published in the journal Nature, identifies how this happens and offers potential new targets for treating intestinal diseases and obesity.
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Publishers, "Placental Growth Factor (PIGF) Blockers-Pipeline Insights, 2016″, report provides in depth insights on the pipeline drugs and their development activities around the Placental Growth Factor (PIGF) Blockers. The Publishers Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publishers Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Placental Growth Factor (PIGF) Blockers. Publishers Report also assesses the Placental Growth Factor (PIGF) Blockers therapeutics by Monotherapy, Combination products, Molecule type and ...
Placenta growth factor (PlGF) is known to induce angiogenesis and protect placental trophoblast from apoptosis. We have shown that PlGF mRNA expression is increased in hypoxic human myocardium and in rat neonatal ...
Angiogenesis, the growth of new blood vessels, is required for the growth of microscopic cancers into larger, clinically relevant tumors (1). The importance of angiogenesis specifically in prostate carcinogenesis is supported by a large body of research, including studies demonstrating altered expression of angiogenic factors in prostate cancer, inhibition of tumor growth in animal models after treatment with angiogenesis inhibitors, and correlations between tumor blood vessel density and both tumor characteristics and clinical outcome (2, 3). Proangiogenic factors important in prostate angiogenesis have been reviewed (2, 3). We selected nine candidate genes, described individually below, which are important in prostate angiogenesis. We then used cases and controls from a large cohort of U.S. men to examine associations between 58 polymorphisms in these genes and risk of advanced and overall prostate cancer.. Vascular endothelial growth factor (VEGF) plays a central role in prostate angiogenesis ...
The Sox family is fundamental for organogenesis and many Sox members frequently cooperate. Sox members cooperate variously depending on the context: redundantly, sequentially, or complementarily. The KAIST team led by Injune Kim unveils a novel cooperation of Sox members for angiogenesis, new blood vessel formation.. This vascular biology team found that loss of any two copies of Sox7 and Sox17 genes in mouse embryo resulted in angiogenic defects, suggesting that Sox7 and Sox17 belonging to the SoxF subgroup genetically cooperates for developmental angiogenesis. VEGF, one of the most powerful stimulators of angiogenesis, upregulated both Sox7 and Sox17 in angiogenic endothelial cells. Both Sox7 and Sox17 increased VEGFR2, the VEGF receptor expressed in endothelial cells. Thus, these results demonstrate that Sox7 and Sox17 jointly promote developmental angiogenesis with overlapping expression and function.. Interestingly, VEGF regulation of SoxF expression and SoxF regulation of VEGFR2 expression ...
Angiogenesis is a multicellular morphogenesis process that expands vascular networks in tissue. Various biological components concertedly contribute to angiogenic morphogenesis. The most important cellular component is endothelial cells, which we use to reconstruct 3D angiogenic process in a extracellular matrix in response to angiogenic growth factors. In addition, perivascular pericytes, blood flow and extravascular tissue importantly serve as (sub)components that allow constructing more sophisticated vascular networks. However, a mechanistic understanding of how the individual components contribute to various angiogenic processes is largely missing. In this seminar, I will introduce a reconstitution angiogenesis assay system with a microfluidic device that allows dissecting the phenomenon in a bottom-up way by adding individual components to the essential one. I will discuss the roles of pericyte and intraluminal pressure on angiogenic morphogenesis based on recent unpublished data obtained ...
Principal Investigator:MAEKAWA Hisato, Project Period (FY):1998 - 1999, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:Gastroenterology
The growth of new blood vessels. When growing in places they shouldnt, they can cause disease, such as wet age-related macular degeneration (AMD). Angiogenesis refers to the growth of new blood vessels. When uncontrolled, angiogenesis can cause destruction of the retina due to leakage of blood.
Angiogenesis is essential for normal retinal development, however pathological retinal angiogenesis can lead to blindness. This occurs in conditions such as ret...
Abstract The Notch signaling pathway is fundamental to proper cardiovascular development and is now recognized as an important player in tumor angiogenesis. Two key Notch ligands h..

Evaluation of ABSOLVE in Diabetic Foot Ulcers - Full Text View - ClinicalTrials.govEvaluation of ABSOLVE in Diabetic Foot Ulcers - Full Text View - ClinicalTrials.gov

Angiogenesis Inducing Agents. Angiogenesis Modulating Agents. Growth Substances. Physiological Effects of Drugs. ...
more infohttps://www.clinicaltrials.gov/ct2/show/NCT03037970

Targeting angiogenesis and the tumor microenvironment.  - PubMed - NCBITargeting angiogenesis and the tumor microenvironment. - PubMed - NCBI

Angiogenesis Inducing Agents. Grant support. *R01 CA142657/CA/NCI NIH HHS/United States ... Targeting angiogenesis and the tumor microenvironment.. Samples J1, Willis M, Klauber-Demore N. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/24012392

Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers - Full Text View - ClinicalTrials.govBecaplermin Gel for MARTORELL's Hypertensive Leg Ulcers - Full Text View - ClinicalTrials.gov

Angiogenesis Inducing Agents. Angiogenesis Modulating Agents. Growth Substances. Physiological Effects of Drugs. ... systemic treatment with corticosteroid agents or cytotoxic drugs in the past 3 months before inclusion ... and/or presence of a diabetes treated by oral agent, insulin or diet ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00970697

Neovascularization | GreenMedInfo | Keyword | Natural MedicineNeovascularization | GreenMedInfo | Keyword | Natural Medicine

Angiogenesis Inducing Agents. 1. 1. *. Research Articles 1. *. Cumulative Knowledge Score 1. ...
more infohttps://www.greenmedinfo.com/keyword/neovascularization

Sarcopenia | GreenMedInfo | Disease | Natural Medicine | AlternativeSarcopenia | GreenMedInfo | Disease | Natural Medicine | Alternative

Angiogenesis Inducing Agents. Additional Keywords : Angiogenesis Inducing Agents, Baicalein, Ovariectomy-Induced Changes, ... Pharmacological Actions : Anti-Inflammatory Agents, Antioxidants. Additional Keywords : anti aging, Anti-Inflammatory Agents, ... Resveratrol enhances exercise-induced cellular and functional adaptations of skeletal muscle in older men and women.May 12, ...
more infohttp://www.greenmedinfo.com/disease/sarcopenia

A Category Names List - Drug Information Portal - U.S. National Library of MedicineA Category Names List - Drug Information Portal - U.S. National Library of Medicine

Angiogenesis Inducing Agents (2). Angiogenesis Inhibitors (29) • Agents and endogenous substances that antagonize or inhibit ... Anti-Angiogenesis Effect (0) see Angiogenesis Inhibitors. Anti-Anxiety Agents (86) • Agents that alleviate ANXIETY, tension, ... Anti-Mycobacterial Agents (0) see Anti-Bacterial Agents. Anti-Obesity Agents (24) • Agents that increase energy expenditure and ... Antithrombotic Agents (0) see Fibrinolytic Agents. Antithyroid Agents (10) • Agents that are used to treat hyperthyroidism by ...
more infohttps://druginfo.nlm.nih.gov/drugportal/drug/categories

Therapeutic angiogenesis with VEGF164 for facilitation of guidewire crossing in experimental arterial chronic total occlusions.Therapeutic angiogenesis with VEGF164 for facilitation of guidewire crossing in experimental arterial chronic total occlusions.

Angiogenesis Inducing Agents / administration & dosage, pharmacology, therapeutic use*. Animals. Arterial Occlusive Diseases / ... 0/Angiogenesis Inducing Agents; 0/Recombinant Proteins; 0/Vascular Endothelial Growth Factor A; 0/vascular endothelial growth ...
more infohttp://www.biomedsearch.com/nih/Therapeutic-angiogenesis-with-VEGF164-facilitation/23339813.html

A Category Names List - Drug Information Portal - U.S. National Library of MedicineA Category Names List - Drug Information Portal - U.S. National Library of Medicine

Angiogenesis Inducing Agents (2). Angiogenesis Inhibitors (29) • Agents and endogenous substances that antagonize or inhibit ... Anti-Angiogenesis Effect (0) see Angiogenesis Inhibitors. Anti-Anxiety Agents (87) • Agents that alleviate ANXIETY, tension, ... Anti-Mycobacterial Agents (0) see Anti-Bacterial Agents. Anti-Obesity Agents (24) • Agents that increase energy expenditure and ... Antithrombotic Agents (0) see Fibrinolytic Agents. Antithyroid Agents (10) • Agents that are used to treat hyperthyroidism by ...
more infohttps://druginfo.nlm.nih.gov/drugportal/jsp/drugportal/drugNamesAndCategories.jsp

Academic Programs Faculty -  Last Initial T - Wake Forest School of MedicineAcademic Programs Faculty - Last Initial T - Wake Forest School of Medicine

Nanofibers; Peptides; Tissue Scaffolds; Angiogenesis Inducing Agents; Hemostatics Academic: 336-716-4498. ...
more infohttp://www.wakehealth.edu/School/FacultySR.htm?st=T&li=T&ft=R

Lack of PTX3 impairs angiogenesis 14 days after middle  | Open-iLack of PTX3 impairs angiogenesis 14 days after middle | Open-i

Lack of PTX3 impairs angiogenesis 14 days after middle cerebral artery occlusion(MCAo). Proliferating vessels (indicated by ... Methods: PTX3 knockout (KO) or wild-type (WT) mice were subjected to experimental cerebral ischaemia (induced by middle ... In vivo poststroke angiogenesis was significantly reduced in PTX3 KO mice compared to WT mice 14 days after MCAo, as revealed ... In vivo poststroke angiogenesis was significantly reduced in PTX3 KO mice compared to WT mice 14 days after MCAo, as revealed ...
more infohttps://openi.nlm.nih.gov/detailedresult.php?img=PMC4308938_12974_2014_227_Fig3_HTML&req=4

Evaluation of vascular regeneration in the striatum on  | Open-iEvaluation of vascular regeneration in the striatum on | Open-i

Angiogenesis Inducing Agents/metabolism. *Animals. *Apoptosis. *Brain Infarction/pathology/physiopathology. *Cell Line ... Background: We previously demonstrated that vascular endothelial growth factor receptor type 2 (VEGF-R2)-positive cells induced ... Background: We previously demonstrated that vascular endothelial growth factor receptor type 2 (VEGF-R2)-positive cells induced ...
more infohttps://openi.nlm.nih.gov/detailedresult.php?img=PMC2567291_1479-5876-6-54-5&req=4

Role of VEGF-A in angiogenesis promoted by umbilical cord-derived mesenchymal stromal/stem cells: in vitro study | Stem Cell...Role of VEGF-A in angiogenesis promoted by umbilical cord-derived mesenchymal stromal/stem cells: in vitro study | Stem Cell...

Angiogenesis was modeled in vitro as tube formation on basement membrane matrix. Progressive differentiation of MSCs to ... for therapeutic angiogenesis. In this report we describe pro-angiogenic properties of UC-MSCs as manifested in vitro. UC-MSCs ... Angiogenesis inducing agents. *CD31 antigen. *Cell migration assays. *Extracellular matrix. Background. The concept of ... Conditioned medium from umbilical cord mesenchymal stem cells induces migration and angiogenesis. Mol Med Rep. 2015;12(1):20-30 ...
more infohttps://stemcellres.biomedcentral.com/articles/10.1186/s13287-016-0305-4

stage iia non small cell carcinoma of the lung drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search enginestage iia non small cell carcinoma of the lung drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

MeSH-major] Angiogenesis Inducing Agents / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / ... Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ... MeSH-major] Angiogenesis Inhibitors / therapeutic use. Angiogenesis Inhibitors / toxicity. Antineoplastic Combined Chemotherapy ... MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug ...
more infohttp://www.bmlsearch.com/?kwr=stage+iia+non+small+cell+carcinoma+of+the+lung+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

melanoma of the cornea drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search enginemelanoma of the cornea drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

MeSH-major] Angiogenesis Inducing Agents / genetics. Antineoplastic Agents / pharmacology. Genetic Therapy / methods. Melanoma ... Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Angiogenic Proteins; 0 / Antineoplastic Agents; 0 / RNA, ... Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / ... MeSH-major] Angiogenesis Inducing Agents / therapeutic use. Angiogenic Proteins / genetics. Genetic Therapy / methods. ...
more infohttp://www.bmlsearch.com/?kwr=melanoma+of+the+cornea+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

Deakin University                                               / All LocationsDeakin University / All Locations

Agents, Angiogenesis Inducing -- See Angiogenesis Inducing Agents Agents that induce or stimulate PHYSIOLOGIC ANGIOGENESIS or ... Agents, Angiogenesis Stimulating -- See Angiogenesis Inducing Agents Agents that induce or stimulate PHYSIOLOGIC ANGIOGENESIS ... Agents used to treat RETROVIRIDAE INFECTIONS 1 Agents, Antiallergic -- See Anti-Allergic Agents Agents that are used to treat ... Agents -- See Agent (Philosophy) 1 Agents, Abortifacient -- See Abortifacient Agents Chemical substances that interrupt ...
more infohttp://library.deakin.edu.au/search~S1?/dAgent+%28Philosophy%29/dagent+philosophy/-3,-1,0,B/browse

Channe Gowda, MSc, PhD - Research Output
     - Penn StateChanne Gowda, MSc, PhD - Research Output - Penn State

Iκb-ζ plays an important role in the ERK-dependent dysregulation of malaria parasite GPI-induced IL-12 expression. Zhu, J., ... Plasmodium falciparum histones induce endothelial proinflammatory response and barrier dysfunction. Gillrie, M. R., Lee, K., ... A malaria protein factor induces IL-4 production by dendritic cells via PI3K-Akt-NF-B signaling independent of MyD88/ TRIF and ... CD36 Contributes to Malaria Parasite-Induced Pro-Inflammatory Cytokine Production and NK and T Cell Activation by Dendritic ...
more infohttps://pennstate.pure.elsevier.com/en/persons/channe-gowda/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Farticle

US7101995B2 - Compositions and processes using siRNA, amphipathic compounds and polycations 
        - Google PatentsUS7101995B2 - Compositions and processes using siRNA, amphipathic compounds and polycations - Google Patents

239000002870 angiogenesis inducing agent Substances 0 description 2 * 230000001772 anti-angiogenic Effects 0 description 2 ...
more infohttps://patents.google.com/patent/US7101995B2/en

US6090618A - DNA constructs and viral vectors comprising a smooth muscle promoter 
        - Google PatentsUS6090618A - DNA constructs and viral vectors comprising a smooth muscle promoter - Google Patents

239000002870 angiogenesis inducing agent Substances 0 description 3 * 230000015572 biosynthetic process Effects 0 description 3 ... 230000033115 angiogenesis Effects 0 claims description 13 * FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound data: ...
more infohttps://patents.google.com/patent/US6090618A/en

Mauro Helmer Citterich - Research Output
     - Italian Ministry of HealthMauro Helmer Citterich - Research Output - Italian Ministry of Health

Angiogenesis Inducing Agents Endothelial Cells Hypertension Genes Human Umbilical Vein Endothelial Cells ... Role of rat α adducin in angiogenesis: Null effect of the F316Y polymorphism. Cappuzzello, C., Melchionna, R., Mangoni, A., ...
more infohttps://moh-it.pure.elsevier.com/en/persons/mauro-helmer-citterich/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Farticle

Mauro Helmer Citterich - Research Output
     - Italian Ministry of HealthMauro Helmer Citterich - Research Output - Italian Ministry of Health

Angiogenesis Inducing Agents Endothelial Cells Hypertension Genes Human Umbilical Vein Endothelial Cells ... Role of rat α adducin in angiogenesis: Null effect of the F316Y polymorphism. Cappuzzello, C., Melchionna, R., Mangoni, A., ...
more infohttps://moh-it.pure.elsevier.com/en/persons/mauro-helmer-citterich/publications/

Sharon Anderson - Publications
     - Oregon Health & Science UniversitySharon Anderson - Publications - Oregon Health & Science University

Angiogenesis Inducing Agents 2001 172 Citations (Scopus) Immunohistochemical and functional correlations of renal ... Impaired angiogenesis in the aging kidney: Vascular endothelial growth factor and thrombospondin-1 in renal disease. Kang, D. H ... K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Levey, A. S., Rocco ...
more infohttps://ohsu.pure.elsevier.com/en/persons/sharon-anderson/publications/

Angiogenic factor: A possible mechanism for neovascularization produced by omental pedicles<...Angiogenic factor: A possible mechanism for neovascularization produced by omental pedicles<...

TY - JOUR. T1 - Angiogenic factor. T2 - A possible mechanism for neovascularization produced by omental pedicles. AU - Cartier, R.. AU - Brunette, I.. AU - Hashimoto, K.. AU - Bourne, W. M.. AU - Schaff, Hartzell V. PY - 1990. Y1 - 1990. N2 - To determine possible mechanisms by which omental pedicles protect bronchial anastomoses from ischemia, we studied the angiogenic potential of a lipid extract of omentum. A rabbit cornea model was used to quantify neovascularization produced by methanol-chloroform extract of homogenized autologous omentum or perirenal fat. In 22 anesthetized rabbits, 10 μl of omental lipid extract was injected into the cornea. In each animal the opposite eye was used as a control and was injected with a similar volume of extract prepared from perirenal fat. The side of injection of autologous omental fat was randomized and was not known to the investigator who assessed neovascularization on days 4, 7, 14, and 21 after injection. Neovascularization was recorded on ...
more infohttps://mayoclinic.pure.elsevier.com/en/publications/angiogenic-factor-a-possible-mechanism-for-neovascularization-pro

Patente US7776025 - Method for providing medicament to tissue - Google PatentesPatente US7776025 - Method for providing medicament to tissue - Google Patentes

... for example an angiogenesis-inducing agent, may be applied through port 336 to the tissue 308′ forming the channel 332. The at ... or any other therapeutic agent or gene therapy agent that promotes angiogenesis or any therapeutic agent for the treatment of ... or any other therapeutic agent or gene therapy agent that promotes angiogenesis. The medicament may be provided to the tissue ... In addition, administering medicaments such as growth factors that promote angiogenesis have been found to promote angiogenesis ...
more infohttp://www.google.es/patents/US7776025

Angiogenesis modulations in health and disease : practical applications of pro- and antiangiogenesis targets [WorldCat Entities]Angiogenesis modulations in health and disease : practical applications of pro- and antiangiogenesis targets [WorldCat Entities]

Angiogenesis Inducing Agents.. This is a placeholder reference for a Topic entity, related to a WorldCat Entity. Over time, ... Angiogenesis Modulating Agents.. This is a placeholder reference for a Topic entity, related to a WorldCat Entity. Over time, ... "Angiogenesis Modulating Agents.". http://experiment.worldcat.org/entity/work/data/1433997986#Topic/angiogenesis_modulating_ ... http://experiment.worldcat.org/entity/work/data/1433997986#Topic/angiogenesis_inducing_agents ...
more infohttp://experiment.worldcat.org/entity/work/data/1433997986
  • Our findings underscore the important role of NADPH oxidase and its subunit p47 phox in modulating Akt and ERK1/2 activation, angiogenic growth factor expression, and angiogenesis in myocardium undergoing I/R. (elsevier.com)
  • Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (nih.gov)
  • The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets. (worldcat.org)
  • Angiogenesis is similar for both genotypes 6 days after MCAo (B), but PTX3 knockout (KO) have less striatal proliferating vessels than wild-type (WT) mice 14 days after MCAo (E), even after normalisation with the total amount of PECAM-1 (E) and (F). Scale bars = 50 μm. (nih.gov)